Verséa Biologics

Verséa Biologics division, headed by Dr. Sunil J. Panchal, M.D., Ph.D., the Chief Scientific Officer and Tyler Johnson, the President, focuses on using the latest cutting-edge scientific advancements in regenerative medicine to provide novel treatment solutions that are fully compliant with the new FDA HCT regulations and use the progenerative power of amnion to help solve debilitating health conditions that millions are suffering from.

An impressive Portfolio is a result of Verséa’s partnership with Celularity, a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.

ADVANCED WOUND CARE

Our Advanced Wound Care Portfolio consists of products that support the body’s natural ability to repair and regenerate, offering the potential to restore tissue (such as chronic wounds) to its pre-wound state with minimal scarring.

(1) BIOVANCE® is a single-layer, easy to use human amnionic membrane allograft intended for use as a biological membrane covering that provides the extracellular matrix that:

  • Reduces inflammation
  • Provides a biological barrier to infection
  • Supports tissue growth
  • Minimizes pain upon application
  • Protects against desiccation and resists proteolyctic enzymes

As a barrier membrane, Biovance® is intended to protect the underlying tissue and preserve tissue plane boundaries with minimized adhesion or fibrotic scarring.

Biovance® is indicated for wound management for a broad set of needs. To learn more, visit biovance.versea.com

(2) INTERFYL® is an allogeneic decellularized particulate human placental connective tissue matrix used for the replacement or supplementation of damaged or inadequate integumental tissue. It does not contain amnion.

Interfyl® is the only registered HCT/P regulated under section 361 of the PHSA that has been granted a “Request for Designation (RFD)” from the FDA. According to the RFD, Interfyl® is designated as a connective tissue matrix to be used for the replacement or supplementation of damaged or inadequate integumental tissue. It serves as a cell-friendly structure for cell attachment within hours, easily incorporating into human body where it supports the body’s natural healing process to repair damaged tissue. To learn more, visit interfyl.versea.com

SURGICAL & SPORTS MEDICINE

Our Surgical & Sports Medicine Portfolio consists of products that support an environment for healing musculoskeletal injuries and degenerative conditions:

(1) INTERFYL® is an allogeneic decellularized particulate human placental connective tissue matrix used for the replacement or supplementation of damaged or inadequate integumental tissue. Interfyl® is the only registered HCT/P regulated under section 361 of the PHSA that has been granted a “Request for Designation (RFD)” from the FDA. According to the RFD, Interfyl® is designated as a connective tissue matrix to be used for the replacement or supplementation of damaged or inadequate integumental tissue. It serves as a cell-friendly structure for cell attachment within hours, easily incorporating into human body where it supports the body’s natural healing process to repair damaged tissue. To learn more, visit interfyl.versea.com

(2) CENTAFLEX® is a decellularized Human Placental Matrix derived from human umbilical cord. CentaFlex has the strength to support repair, without the trade-off of an overly thick tissue. It is used as a barrier or wrap to cushion and protect the surgical site and support wound management during healing. It is intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. As a barrier membrane, CentaFlex is intended to protect the underlying tissue. Indications include, but are not limited to, surgical covering, wrap or barrier. To learn more, contact us at biologics@versea.com.

(3) BIOVANCE® 3L is a three-layered human amnionic membrane allograft intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. As a barrier membrane, 3L is intended to protect the underlying tissue and create a barrier between the tissue plane boundaries. Indications include, but are not limited to, surgical covering, wrap or barrier, application to partial- and full-thickness, acute and chronic wounds (such as, traumatic and complex wounds, burns, surgical and Mohs surgery sites; and diabetic, venous, arterial, pressure and other ulcers), including wounds with exposed tendon, muscle, bone or other vital structures. To learn more, contact us at biologics@versea.com.

OPTHALMIC CARE

Our Ophthalmic Care Portfolio contains novel, innovative solutions for the eye care.

BIOVANCE 3L OCULAR is a new-gen ringless “hybrid” human amniotic membrane designed for early treatment of ocular surface diseases. It is a novel configuration for patient comfort and differentiated outcomes. It is THE ONLY DECELLULARIZED, THREE LAYERED human amniotic membrane that provides enhanced cellular scaffolding that facilitates early epithelial cell adhesion, self-induced
cytokine production, and accelerated wound repair. To learn more, visit biovance-3l-ocular.versea.com

FULL SERVICE IN-OFFICE INJECTION PLATFORM FOR HCT/P

Our Platform has been created to help maximize revenues and dispose of missed collection opportunities on every claim submitted.  The services include:

  • Handling of all pre-auths and/or pre-determinations
  • Vetting every policy to ensure that there are no edits, exclusions, or provisions, that would prevent the claim from adjudicating. Building a defensible bill charge to prevent any claw backs or recoupments. Getting an approval with a reference # on a recorded line (with a 98% adjudication rate)
  • Staying completely away from traditional Red, White, & Blue Medicare because there is no guidance in the Local Coverage Determination (LCD) or National Coverage Determination (NCD) policies.
  • Focusing on Medicare Advantage plans, commercial plans, & VA benefits (Optim/TriWest). Most of Medicare Advantage & VA plans, and some of commercial plans have built in policy specific Human Cell Tissue Products (HCT/P) coverage. Unlike traditional Medicare, there is clear guidance in the LCD & NCD policies for coverage of HCT/P’s.

The reason that providers like the Platform is because there is no upfront cost for the practice.

To learn more, contact us at biologics@versea.com or click the CONNECT WITH US button below.

Partner with us

The Verséa Biologics expert team is looking forward to partnering with Physicians interested in offering effective regenerative medicine treatment options to their patients.

If you want to receive more information about our regenerative, biologics products, let us know!